VP4 Stock Overview
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Vistin Pharma ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr2.03 |
| 52 Week High | kr2.05 |
| 52 Week Low | kr1.79 |
| Beta | 0.90 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -24.68% |
| 5 Year Change | n/a |
| Change since IPO | 109.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| VP4 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | n/a | -1.0% | -1.7% |
| 1Y | n/a | -30.1% | 1.4% |
Return vs Industry: Insufficient data to determine how VP4 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how VP4 performed against the German Market.
Price Volatility
| VP4 volatility | |
|---|---|
| VP4 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: VP4 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine VP4's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1969 | 78 | Magnus Tolleshaug | www.vistin.com |
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Vistin Pharma ASA Fundamentals Summary
| VP4 fundamental statistics | |
|---|---|
| Market cap | €87.68m |
| Earnings (TTM) | €3.92m |
| Revenue (TTM) | €37.68m |
22.3x
P/E Ratio2.3x
P/S RatioIs VP4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VP4 income statement (TTM) | |
|---|---|
| Revenue | kr438.33m |
| Cost of Revenue | kr176.64m |
| Gross Profit | kr261.68m |
| Other Expenses | kr216.04m |
| Earnings | kr45.64m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 24, 2024
| Earnings per share (EPS) | 1.03 |
| Gross Margin | 59.70% |
| Net Profit Margin | 10.41% |
| Debt/Equity Ratio | 0% |
How did VP4 perform over the long term?
See historical performance and comparisonDividends
4.3%
Current Dividend Yield97%
Payout RatioDoes VP4 pay a reliable dividends?
See VP4 dividend history and benchmarks| Vistin Pharma dividend dates | |
|---|---|
| Ex Dividend Date | Jun 05 2024 |
| Dividend Pay Date | Jun 18 2024 |
| Days until Ex dividend | 50 days |
| Days until Dividend pay date | 63 days |
Does VP4 pay a reliable dividends?
See VP4 dividend history and benchmarks